NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because Novartis did not provide a complete evidence submission.
Guidance development process
This advice updates and replaces NICE technology appraisal guidance 567 on tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies, which was available through the Cancer Drugs Fund. People already having it will be able to continue until they and their doctor decide when best to stop.